| Nov 19 |
Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution
|
| Nov 12 |
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
|
| Nov 12 |
Roivant Sciences Ltd. 2024 Q2 - Results - Earnings Call Presentation
|
| Nov 12 |
Roivant Sciences GAAP EPS of -$0.25, revenue of $4.48M
|
| Nov 12 |
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Oct 29 |
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
|
| Oct 28 |
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
|
| Oct 22 |
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
|
| Sep 19 |
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
|
